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Summary Quality of life (QL) is used to assess treatments in clinical trials but may be influenced by other factors. We analysed the impact of
biomedical, sociodemographic and cultural factors on baseline OL indicators in two Intemational Breast Cancer Study Group trials. Patients
with stage 11 breast cancer were randomized within 6 weeks of primary surgery to various adjuvant treatments. They were asked to assess
five indicators of QL at baseline. OL forms were available for 1231 (830/o) of the 1475 premenopausal and 989 (82%) of the 1212 post-
menopausal patients, who were from nine countries and spoke seven languages. Culture (defined as language/country groups) had a
statistically significant impact on baseline OL measures. Premenopausal patients with poor prognostic factors showed a tendency to report
worse QL, with oestrogen receptor status as an independent predictor for mood (P= 0.0005). Older post-menopausal patients reported better
emotional wellbeing (P = 0.002), mood (P = 0.002), and less effort to cope (P = 0.0009) compared with younger post-menopausal patients.
Co-morbidity, type of surgery, treatment assignment and sociodemographic factors showed a statistically significant impact in post-
menopausal patients only. Cultural and biomedical factors influenced baseline QL and should be considered when evaluating the impact of
treatment on OL in international breast cancer clinical trials.
Keywords: quality of life; breast cancer; cross-cultural issues; language; international trial
The methodology ofinternational cancerclinical trials is constantly
being improved and adapted as clinical questions evolve. The most
recent step in this evolution is the inclusion ofpatient-rated quality
oflife (QL) as an end point for treatment comparison.
Social and cultural factors are an integral part of any indi-
vidual's estimation or judgement of QL. The principles of QL
assessment. however. have been established mostly within
regional or national settings. Evaluating these social and cultural
factors has only recently received attention. particularly in cancer
clinical trials involving participants from multiple cultures (Hurny
et al. 1992). The influence of such factors on cancer treatment
comparisons based on QL is uncertain. and methods to adjust for
them have rarely been discussed (Bernhard et al. 1996: Cella et al.
1996). We wished to examine the impact of social and cultural as
well as biomedical factors. such as co-morbidity and prognostic
factors at diagnosis. on patients' self-report of the experience of
beginning treatment.
We examined three specific hypotheses. Based on prior experi-
ence in the Group. we expected substantial heterogeneity of base-
line QL in the various languagelcultural groups: we expected worse
baseline QL with worse prognostic factors. both because percep-
tion ofthese factors may colour the information given to the patient
and because worse QL had previously been reported among
patients with receptor-negative tumours (Razavi et al. 1990). and
we expected worse baseline QL scores in patients living alone or
only with children. based on the social support paradigm.
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We therefore analysed the relationship between biomedical.
sociodemographic and cultural factors and five indicators of
components ofQL recorded at baseline assessment in two intema-
tional adjuvant breast cancertrials (Hurny et al. 1996a). This inves-
tigation identified covariates which need to be considered when
interpreting baseline QL and evaluating the influence of treatment
factors on QL in international breast cancer clinical trials.
METHODS
The trials
Between July 1986 and April 1993. two International Breast
Cancer Study Group (IBCSG) trials examined similar questions of
timing and duration ofadjuvant cytotoxic therapy for patients with
node-positive operable breast cancer. In trial VI. we randomized
1475 eligible premenopausal and perimenopausal patients in a
2 x 2 factorial design to receive three or six initial cycles of
chemotherapy using oral cyclophosphamide. intravenous
methotrexate and 5-fluorouracil (CMF). with or without three later
single cycles of reintroduction CMF administered at 3-month
intervals. At the same time. 1212 eligible post-menopausal
patients were randomized in IBCSG trial VII. All post-
menopausal patients received 20 mg of tamoxifen daily for 5
years. Tamoxifen alone was compared with chemo-endocrine
therapy. adding three initial cycles of CMF. three delayed CMF
cycles administered at months 9. 12 and 15 or both early and
delayed CMF. Eligibility criteria have been reported (International
Breast Cancer Study Group. 1996. 1997). The randomization in
both trials was stratified by institution. type of surgery and
oestrogen receptor (ER) status. The participating institutions from
nine countries are listed in the Appendix.
Members ofthe International Breast Cancer Studs Group are listed in the Appendix.
686Impact on baseline quality oflife 687
0L assessment
The QL form included five indicators of components of health-
related QL especially relevant in adjuvant breast cancer patients
(Hurny et al. 1992). Physical wellbeing. mood. appetite (Priestman
and Baum. 1976: Coates et al. 1987) and perceived adjustment to
chronic illness (PACIS) (Hurny et al. 1993) were assessed with
single-item linear analogue self-assessment (LASA) scales. previ-
ously validated in several cancer populations (Coates et al. 1983:
Coates et al. 1990: Butow et al. 1991). An additional assessment of
emotional wellbeing used the 'Befindlichkeitsskala' (Bf-S). a
psychometrically characterized 28-item adjective checklist
(Zerssen. 1976: Zerssen. 1986). The relationship between the
mood LASA and the Bf-S has been reported elsewhere (Hurny et
al. 1996b). QL forms were translated into the seven required main
languages by professional translators, pilot tested by physicians
and patients in the relevant centres and adjusted in the light oftheir
feedback to ensure not only linguistic. but also conceptual.
equivalence. The LASA translations were further checked by an
independent forward-backward' translation procedure.
In accordance with prior validated use of these instruments.
patients were asked to fill in the scales referring to different time
frames. The LASA scales forphysical wellbeing. mood and appetite
were related to the 'entire period since your last full clinical assess-
ment'. while the Bf-S was related to the 'present state or the way
you feel now'. The time frame ofthe PACIS was not specified.
The protocols required that adjuvant therapy began within 6
weeks of surgery and that patients completed the baseline QL
questionnaire on. or as close as possible to. day I of adjuvant
therapy. before the administration of treatment. The actual timing
with respect to surgery and the time at which the patient received
information about her tumour varied according to the institution
and the individual case. Overall. ofthe 1724 patients who received
initial chemotherapy. 1421 patients (82%) completed the QL ques-
tionnaire either exactly as required (1052 patients: 61%) or before
(369 patients: 21%). while 303 patients (18%) completed the
questionnaire later.
Language/cultural, biomedical and sociodemographic
factors
Biomedical factors investigated were age (for premenopausal and
perimenopausal women. age was grouped as under 45 or 45 and
older, forpost-menopausal women. age was grouped as under 60or
60 and older): oestrogen receptor (ER) and progesterone receptor
status (negative vs positive. defining positive as 10 fmol mg-'
cytosol protein or greater): extent of primary surgery (total
mastectomy vs conservative surgery plus radiotherapy): presence
of concomitant chronic disease; treatment assignment: number of
positive axillary nodes: and clinical tumour size (< 2 cm vs
> 2 cm). For this analysis we used clinical tumour size. as it was
expected to be more relevant to patients' perceptions than patho-
logical measurements. Sociodemographic factors investigated were
marital status (married. divorced or separated. widowed. single):
living situation (alone. with spouse or partner. with children. with
others): employment status (full or part time. housewife. unem-
ployed. other): occupation (housewife or retired. self-employed.
white collar/upper level management. white collar/subordinate and
blue collar): educational level (none/primary. secondary. tertiary.
and also by total years grouped as 0-5.6-7.8-9. 10-12. more than
12): and reported income level (grouped simply as below average.
Table 1 Number of patients and institutions according to trial and cultural
group
Cultural group Number of Number of patients
institutions
Country Language Trial VI Trial Vii
Australia/New Zealand English 6 315 187
South Africa English 1 43 49
Switzerland French 3 63 54
Switzerland/Germany German 6 203 166
Switzerland Italian 1 42 57
Italy Italian 3 157 164
Slovenia Slovenian 1 138 97
Spain Spanish 1 49 20
Sweden Swedish 1 221 195
Total 9 7 22a 1231 989
One Swiss institution is represented in both the Swiss German and the
Swiss Italian cultures.
Table 2 Mood means according to culture (sorted by mean tnal Vl value)
Trial VI Trial Vii
Country, LASA n Meanb n Meanb
Language anchorsa (95% CI) (95% CI)
Slovenia. Srecna 130 54.6 87 68.4
Slovenian Nesrecna (48.9. 60.0) (62.4. 74.0)
Sweden, Lycldig 221 62.9 194 66.5
Swedish Olyckdig (58.9, 66.6) (62.4. 70.4)
Switzerland/ Giicidich 196 70.8 155 71.8
Germany, (67.1. 74.3) (67.5,75.7)
German UnglCicldich
Spain, Feliz 49 71.7 20 76.9
Spanish Desdichada (64.1. 78.4) (65.4. 86.1)
Italy, Buono 156 74.2 162 73.9
Italian Pessimo (70.2, 77.9) (69.9. 77.6)
Switzerland. Bon 63 74.1 52 82.0
French Mauvais (67.7. 79.8) (75.9. 87.2)
Australia/ Happy 309 77.9 184 81.6
New Zealand, (75.4. 80.4) (78.4. 84.5)
English Miserable
South Africa. Happy 43 79.3 49 81.7
English Miserable (72.2, 85.3) (75.3. 87.1)
Switzerland, Buono 42 83.8 57 84.4
Italian Pessimo (77.4, 89.1) (79.0, 89.1)
Patients were asked to mark a cross on a 100-mm line to rate mood overall
for the entire period since their last full clinical assessment Higher scores
reflect better mood. "Transformed mean as described in Statistical methods.
average. above). Culture was defined by nine broad language/
country groupings (English/Australia or New Zealand: English/
South Africa: French/Switzerland: German/Switzerland or
Germany: Italian/Switzerland: Italian/Italy: Slovenian/Slovenia:
Spanish/Spain: Swedish/Sweden). recognizing that in these data
language is inextricably associated with culture. German-speaking
patients from Switzerland and Germany were combined because
there were only 14 from Germany.
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Table 3 Summary of the impact of biomedical factors on baseline OL measures in trial VI and VII (two-sided P-values)
Emjobo Mood Ph A mpe A _
welfbeing welbeing (PACIS)
(Bf-S)
VI Vll VI Vl VI Vi VI vH VI Vii
Non-tumour
related factors
Age: 60+ (VII)
0.002 0.002 0.0009
Chronic disease:
no
0.02
Treatment
assignment less
chemotherapy 0.007
Tumourrelated
factorsa
ER status: 0.0005
positive
Progesterone
receptor status
Number of
positive nodes:
fewer positive
nodes
0.01 0.003 0.05 0.0008
Tumour size
Type of surgery:
mastectomy
0.006
aCategory of factor associated with higherQL scores.
Table 4 Emotonal wellbeing, mood and aqustment means according to age in post-menopausal patents (trial VII)
OL scale Age n Hem? (95% Cl) P
Emotional wellbeing (Bf-S) < 60 432 75.9 (73.9,77.8) 0.002
60+ 510 80.0 (78.3, 81.6)
Mood < 60 434 72.1 (69.6, 74.5) 0.002
60+ 526 77.1 (75.0, 79.0)
Adjustment (PACIS) < 60 437 64.5 (61.7, 67.2) 0.0009
60+ 532 70.5 (68.2,72.7)
aTraJsfofned mean asdescribed in Statisbcal methods.
Statistical methods
The LASA scales were scored by measuring in millimetres from 0
to 100, with higher numbers reflecting better QL. and the scores
forthe Bf-S were transformed to have the same range and interpre-
tation. We used a transformation (the square root of 100 minus
these scores) in all analyses, since this transformation approxi-
mated a normal distribution and stabilized the variances, but all
results are reported in the 0 to 100 scale (100 minus the squares of
the estimated means of the transformed scores). Because the
square root transformation approximates a symmetric distribution,
these 'transformed means' are approximate estimates of medians.
Analyses of variance (ANOVA) were used to test for associations
between baseline QL measures and various cultural, biomedical
and sociodemographic factors. We previously showed that
language had a significant influence on the QL scores obtained
from our instruments (Hurny et al. 1992). Therefore. for this
analysis we grouped patients into the nine language/country
groups listed above and assessed each of the biomedical and
sociodemographic factors controlling for culture but not for the
other factors, fitting a separate ANOVA model for each ofthe five
QL measures within each ofthe two trials. In addition. we investi-
gated interactions between selected factors that we had found to be
associated with baseline QL. We report transformed means stan-
dardized to the overall distribution ofcultures within each trial. No
adjustment was made for multiple comparisons: two-sided P-
values were used as descriptive statistics to identify associations in
the observed results.
As previously shown, baseline QL scores can vary with time
from start of chemotherapy (Hurny et al, 1994). In this analysis.
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controlling for timing when testing the significance of culture did
not change our conclusions. We did not control for timing when
testing for biomedical and sociodemographic factors, because we
expected that the effects oftiming would be independent of these
factors; overall. the proportion ofthe variance explained by timing
was small.
RESULTS
Description of the sample
Baseline QL assessments were completed by 1262 (86%) of the
1475 trial VI patients and by 1008 (83%) of the 1212 trial VII
patients. Compliance rates varied considerably among institutions.
from 58% to 100% in trial VI and from 59% to 100% in trial VII.
Excluded from this investigation were 50 patients from four coun-
tries who did notcomplete the QL form in theprimary language of
their region of their country (31 from trial VI, 19 from trial VII).
Table 1 shows the culture groups, along with the number of
institutions and the number ofpatients included in each.
Cultural factors
Overall. cultural factors had the strongest impact on baseline QL
and affected all five measures in both trials (P < 0.0001 for all.
except for appetite and physical wellbeing in trial VII, which were
P = 0.05 and 0.003 respectively). For example, Table 2 shows the
means ofthe mood scale according to culture. The pattern ofmood
scores across culture groups was similar within the two trials.
Two of the languages were used in more than one country.
allowing for comparisons between countries within the same
language. QL scores for English-speaking patients from
Australia/New Zealand were similar to those forEnglish-speaking
patients from South Africa (Table 2). In contrast. Italian-speaking
patients from northern Italy reported substantially lower mood
scores than those from the adjoining southern part of Switzerland
(P = 0.01 in trial VI. P = 0.002 in trial VII; Table 2). All other QL
scales showeddifferences in the same direction, although not all of
the differences were statistically significant.
Overall. the variance explained by these cultural factors was
modest. It ranged from 3% (Bf-S. physical wellbeing) to 8%
(mood) in trial VI (premenopausal and perimenopausal patients).
and from 2% (physical wellbeing. appetite) to 6% (mood. PACIS)
in trial VII (post-menopausal patients).
Biomedical factors
After controlling for cultural effects, biomedical factors also had
an impact on the QL measures, as summarized in Table 3. The
mood and adjustment scales were most responsive to these factors.
The effects of tumour and non-tumour related biomedical factors
were different in the two trials.
Age had a significant impact in post-menopausal patients only.
Olderpatients (60+ years) reported better emotional wellbeing (P =
0.002) and mood (P = 0.002), and less effort to cope (P = 0.0009)
compared with younger post-menopausal patients (Table 4).
Although olderpatients were more likely to have total mastectomies
(71% for patients under 55 years to 79% for patients 65 years and
alder), the age effect was independent oftype ofprimary surgery.
Presence of concomitant chronic disease was associated with a
tendency to worse physical wellbeing in post-menopausal patients
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Figure 1 Impact oftumourfactors on mood scores in premenopausal
patients. (A) Transformed mean mood score by ER status. (B) Transformed
mean mood score by number of positive nodes
(no co-morbidity: mean = 79.7: with co-morbidity: mean = 76.2.
P = 0.02). As expected, co-morbidity was more prevalent in post-
menopausal (33%) than premenopausal (13%) patients. Type of
surgery had an impact on mood in post-menopausal patients only.
Those treated with mastectomy reported better mood scores than
those treated with conservation plus radiotherapy (76.1 vs. 70.8.
P = 0.006). An effect of systemic adjuvant treatment assignment
was observed in trial VII. Patients assigned to receive tamoxifen
only reported betterappetite (mean = 88.3) than those who were to
undergo additional early (mean = 82.7), late (mean = 83.6). or
early and late chemotherapy (mean = 84.5, P = 0.007).
In general, patients whose tumours had characteristics associ-
ated with poorer prognoses reported worse QL. Premenopausal
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patients with ER-negative tumours reported worse mood than those
with ER-positive tumours (67.2 vs. 73.0; P = 0.0005). Higher
numbers ofpositive nodes were associated with worse mood in both
premenopausal (P = 0.003) and post-menopausal patients (P = 0.05)
and with worse emotional wellbeing in post-menopausal patients
(P = 0.01); adjustment was negatively affected by status in
premenopausal patients only (P = 0.0008). ER status and number of
positive nodes were both independent predictors of mood in
premenopausal patients (P = 0.0004 for ER status adjusted for
number of positive nodes: P = 0.002 for number of positive nodes
adjusted for ER status). The association with ER status was seen in
eightofthe nine cultural subgroups (P < 0.05 forFrench/Switzerland
and Spain); the difference was small and not statistically significant
in the one subgroup in which the direction ofthe difference was the
opposite (Italy). Figure 1 shows mean mood scores according to ER
status and numberofpositive nodes in all premenopausal patients.
Socdernographic factors
Sociodemographic factors were significantly associated with QL
in post-menopausal. but not premenopausal, patients. Married and
separated or divorced post-menopausal patients reported better
emotional wellbeing (Bf-S) than those who were widowed or
single (mean of married = 79.2, separated/divorced = 80.1,
widowed = 75.3. single = 75.0: P = 0.05). Living alone was asso-
ciated with poorer emotional wellbeing (mean = 75.3) than living
with others (mean for women living with spouse orpartner = 78.9.
with children = 77.3. with other = 83.4; P = 0.05). Living alone or
with children was associated with worse appetite than living with
spouse. partner orother (mean for women living alone = 81.8. with
children = 83.2, with spouse or partner = 85.8 with other = 88.4:
P = 0.05). Post-menopausal women with either little formal
schooling or with extensive education reported worse adjustment
than women with levels in between (mean for 0-5 years = 67.1, 6
or 7 years = 66.5. 8 or 9 years = 69.0. 10-12 years = 70.6, more
than 12 years = 59.4; P = 0.04).
Country differences within language
We also investigated whetherornot there was adifferential impact
ofbiomedical and sociodemographic factors on global QL indica-
tors between different countries within the same language group.
Mood and adjustment were analysed separately in the two
English-speaking groups (South Africa and Australia/New
Zealand) within each trial and in the two Italian-speaking groups
(Italy and Switzerland) within each trial. Although some differ-
ences were observed, there were no consistent patterns, suggesting
that these factors have a similar impact on patient self-estimation
within language groups. They do not explain the overall difference
in mood between Italian-speaking patients from Italy and Italian-
speaking patients from Switzerland.
DISCUSSION
Individual patients' baseline QL scores vary considerably within
cancer clinical trials. They are highly predictive of the level of
subsequent QL assessments and therefore relevant for investi-
gating treatment-related changes. We analysed how biomedical.
sociodemographic and cultural factors affected baseline scores of
two large-scale adjuvant breast cancer trials (Hurny et al. 1996a)
and now report these associations in more detail. This information
will be useful for investigators in determining which additional
variables need to be assessed in breast cancer clinical trials.
Cultural factor
This investigation has confirmed and substantially extended our
previous report (Hurny et al. 1992) that cultural and language
factors affect patient-rated QL and, therefore. need to be consid-
ered in cross-cultural trials. although their contribution to the total
variance in QL scores is modest. Although it remains possible that
these findings are due to imperfect translation, we believe this is
unlikely given the thorough multistep translation procedure which
was used.
Before concluding that there are 'true' cultural differences. we
should also consider institutional factors and the possibility of
selective recruitment of patients with different characteristics, or
differences in patient care in the various cultures. This may
account for the differences seen between the Italian-speaking
Swiss andthepatients from northern Italy. The participating hospi-
tals in Italy are larger, the waiting rooms are more crowded. and
patients may feel more anonymous at the beginning of treatment
than in the Swiss outpatient clinics. Also, the generally higher QL
scores in Switzerland compared with Slovenia may reflect true
overall socioeconomic differences between the two countries. It is
also possible that systematic differences among cultures in the
degree and method of doctor-patient communication about the
details of the tumour and its treatment may underlie part of the
observed cultural differences in QL.
On the other hand, in the case that patients from different
cultures report similar QL scores (e.g. English-speaking patients
from Australia/New Zealand and South Africa), this similarity
may hide true cultural differences in perceptions, attitudes and
habits. Although these differences are not relevant for overall
treatment comparisons, in subgroup analyses an isolated interpre-
tation of either symptoms or any aspect of QL without regard to
the institutional, social and cultural context could be misleading
(Huimy et al, 1993).
In summary, the overall differences among the investigated
cultures probably reflect cultural differences in patients' response
to disease and treatment sequelae, such as a tendency to stoic self-
control orexasperated emotional expression in particular cultures.
This is especially relevant for highly 'subjective' concepts such as
'coping' (PACIS). but was also seen in appetite, a relatively
concrete sensation.
Biomedical factors
Age had an effect on QL in post-menopausal patients only. Post-
menopausal patients under 60 reported worse emotional and
adjustment scores than older patients. To our knowledge. the role
of age in the adjustment to diagnosis and treatment has not been
reported separately within menopausal status groups (Vinokur et
al, 1990; Ganz et al, 1993: Mor et al. 1994), except in one study in
which increased anxiety was observed in patients in their fifties
treated by mastectomy (Maraste et al, 1992).
Co-morbidity was much more frequent in post-menopausal
patients. It had a weak negative impact on physical wellbeing in
both trials, but was significantly associated with physical well-
being only in post-menopausal patients.
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Extent of surgery was a significant factor associated with mood
in post-menopausal patients, with patients who had had total
mastectomies reporting better mood scores. At the start of adju-
vant therapy. emotional distress is characterized by anxiety rather
than depression (Maraste et al. 1992). A total mastectomy could
have relieved anxiety regarding disease progression in these
patients (Fallowfield et al. 1990). whereas in premenopausal
patients other factors. such as concerns about body image, may
dominate. Radiotherapy was given only after breast conservation.
and followed chemotherapy. Its anticipation might have
contributed to increased anxiety in the group treated by breast
conservation. Other reports do not suggest a relationship between
extent of surgery and either psychological distress or physical
dysfunction at this early phase of recovery from surgery (Kiebert
et al. 1991; Ganz et al. 1992: Pozo et al. 1992). The relationship
between ER status and mood is in agreement with the finding
reported by Razavi (1990). but has not been confirmed by other
groups (Hislop and Kan. 1990; Maunsell and Bnsson. 1990:
Rosenqvist et al. 1993: Tjemsland et al. 1995). It may reflect either
an intrinsic interaction between emotional processes and the
endocrine system in premenopausal patients or the psychological
impact of the physician having communicated to the patient infor-
mation regarding herprognosis (Roberts et al. 1994). Interestingly.
the association between ER status and perceived adjustment.
which is not a pure emotional concept but has also a strong cogni-
tive component. was not significant. On the other hand- the rela-
tionship between number of positive nodes and both emotional
measures and adjustment may reflect patients' response to having
received information regarding nodal involvement and its prog-
nostic significance. The exact procedure and timing of patient
information may have varied among and even within institutions.
These issues cannot be further clarified with our data.
Nevertheless, this finding is intriguing and warrants further study.
especially in regard to treatment effects on QL and to biomedical
outcome (Coates et al. 1992: Hurny, 1993).
The effect of treatment assignment on appetite in post-
menopausal patients is probably an anticipatory effect. Patients
were informed about the allocated treatment beforecompleting the
QL form. patients assigned to receive tamoxifen only reported
better baseline appetite scores than those assigned to receive late
chemotherapy only. As reported in the analysis of the impact of
treatment on subsequent QL in these trials (Hurny et al. 1996a).
anticipation of treatmentplays a role inpatients' perception ofQL.
Overall, biomedical factors showed little impact on baseline
QL. Because treatment trials are stratified by major biomedical
prognostic factors. they are primarily relevant for subgroup
comparisons. Our findings contrast with those of a smaller investi-
gation of 109newly diagnosed breast cancerpatients. which found
no significant association between patient-rated rehabilitation
needs and axillary node status, type of surgery or receipt of
chemotherapy (Ganz et al. 1990). It is not clear whetherthis differ-
ence is due to the different QL measures (global indicators vs
specific problem evaluation) or due to the different study contexts.
In our study. mood and adjustment. those measures most closely
reflecting patients' 'subjective' experience. were the most sensi-
tive to biomedical factors.
Sociodemographic factors
Sociodemographic factors showed a relatively weak association
with baseline QL. which was seen in post-menopausal patients
only. Overall, we found no major effect of these factors on QL.
However. these factors have been shown to predict survival in
breast (Karjalainen and Pukkala. 1990: Schrijvers et al. 1995) and
othercancers. and we suggest that in large-scale international trials
at least one indicator of socioeconomic status (e.g. educational
level) be recorded.
Furher investigations
More information is needed about the perception and under-
standing ofcancer and its treatment in various cultures. The ques-
tion of how interactions among cultural. social and biomedical
factors affect QL in cancer clinical trial settings warrants further
study. notjust forbaseline scores, but also forQL during treatment
and follow-up. In addition. the generalizability of the effect of
biomedical interventions on QL should be investigated within
international clinical trials.
Only a modest part ofthe variance in QL scores was explained
by the factors investigated. In contrast, individual psychosocial
factors, such as stressful life events before diagnosis (Maunsell et
al. 1992). history of depression (Maunsell et al. 1992). attitudes
(Carver et al. 1994) and social support (Irvine et al. 1991) have
been reported to be substantially associated with patients' adjust-
ment. Their impact as covariates in evaluating treatment effects on
QL could not be investigated in the present study.
Conclusions
Cultural factors have a substantial impact on baseline QL
measures, although they explain only a small percentage of the
total variance. They need to be considered when evaluating the
influence oftreatment on QL in international breast cancer clinical
trials. Various biomedical factors have a less pronounced but
tangible impact Their effects are different in premenopausal
compared with post-menopausal patients.
ABBREVIATIONS
ANOVA. analysis of variance: Bf-S, Befindlichkeitsskala; CMF.
combination chemotherapy using oral cyclophosphamide plus
intravenous methotrexate and 5-fluorouracil: ER. oestrogen
receptor, IBCSG. International Breast Cancer Study Group:
LASA. linear analogue self-assessment: PACIS. perceived adjust-
ment to chronic illness scale; QL. quality of life
ACKNOWLEDGEMENTS
We gratefully acknowledge the support for central trial coordina-
tion. data management and statistics provided by the Swiss
Cancer League, Cancer League of Ticino, Swiss Group for
Clinical CancerResearch, Australian-New Zealand Breast Cancer
Trials Group, the Australian Cancer Society, Frontier Science and
Technology Research Foundation, and grant PBR-53 from the
American Cancer Society. The trials were also supported by the
National Health and Medical Research Council of Australia. the
Anti-Cancer Council ofVictoria and the New South Wales Cancer
Council. These data reflect the efforts ofour patients. nurses, data
managers and physicians. Without their enthusiastic cooperation
across disciplines, national borders and cultures, studying quality
of life in international cancer clinical trials would not be possible.
We are especially grateful to Mary Isley. Rita Hinkle and Heidi
BritishJournalofCancer(1998) 78(5), 686-693 0CancerResearch Campaign 1998692 J Bemhardetal
Gusset, who were responsible for central QL data management.
We also would like to thank Christoph Minder for his contribution
to the analysis ofcultural and sociodemographic factors.
REFERENCES
Bernhard J. Hirnv C. Coates AS and Gelber RD (1996) Applying quality oflife
principles in internatonal cancer clinical trials. In Quality ofLife and
Pharmacoeconomics in Clinical Trials. B Spilker (ed). pp. 693-705.
Lippincott-Raven: Philadelphia
Butow PN. Coates AS. Dunn S. Bernhard J and Hirny C (1991) On the receiving
end- IV: Validation ofquality oflife indicators. Ann Oncol 2: 597-603
Carver CS. Pozo Kaderman C. Harris SD. Noriega V. Scheier MN. Robinson DS.
Ketcham AS. Moffat Jr FL and Clark KC (1994) Optimism versus pessimism
predicts the quality ofwomen's adjustment to early stage breast cancer. Cancer
73:1213-1220
Cella DE Lloyd S and Wright B (1996) Cross-cultural instrument equating: current
research and future directions. In Qualizv ofLife andPharmacoeconoeics in
Clinical Trials. B Spilker (ed). pp. 707-715. Lippincott-Raven: Philadelphia
Coates AS. Fischer-Dillenbeck C. McNeil DR. Kaye SB. Sims K. Fox RM. Hedley
DW. Raghavan DR. Woods RL Milton GW and Tattersall MHN (1983) On the
receiving endI H. Linear analogue selfassessment in the evaluation ofquality
oflife ofcancerpatients. EurJCancerClin Oncol 19: 1633-1638
Coates AS. Gebski V. Bishop JF. Jeal PN. Woods RL Snyder R. Tattersall MHN.
Byrne M. Harvey V. Gill PG. Simpson J. Drummond R. Browne J. Van Cooten
R and Forbes JF (1987) Improving the quality oflife in advanced breast cancer.
A comparison ofcontinuous and intermittent treatment strategies. N Engl J
Med317: 1490-1495
Coates AS. Gebski V. Signorini D. Murray P. McNeil D. Byrne M and Forbes JF
(1992) Prognostic value ofquality-of-life scores during chemotherapy for
advanced breast cancer. Australian New Zealand Breast CancerTrials Group
[see comments]. JClin Oncol 10: 1833-1838
Coates AS. Glasou PP and McNeil D (1990) On the receiving end. m: Measurement
ofquality oflife during cancerchemotherapy. Ann Oncol 1: 213-217
Fallowfield LU. Hall A. Maguire GP and Baum M (1990) Psychological outcomes of
different treatment policies in women with early breast cancer outside a clinical
trial. BrMedJ301: 575-580
Ganz PA. Hirji K. Sim MS. Schag CA. Fred C and Polinsky ML (1993) Predicting
psychosocial risk in patients with breast cancer. Med Care 31: 419-431
Ganz PA. Schag AC. Lee JJ. Polinsky ML and Tan SJ (1992) Breast conservation
versus mastectomy. Is there a difference in psychological adjustment or quality
oflife in the year aftersurgery Cancer6W: 1729-1738
Ganz PA. Schag CA and Cheng HL (1990) Assessing the quality oflife - a study in
newly-diagnosed breast cancer patients. J Clin Epidemiol 43: 75-86
Hislop TG and Kan L (1990) Receptor status and psychological adjustment ofbreast
cancer patients (letter). Lancet336: 47-48
Hiirny C (1993) Coping and survival in early breast cancer- an update. Recent
Results Cancer Res 127: 211-220
Hirny C. Bernhard J. Bacchi M. van Wegberg B. Tomamichel M. Spek U. Coates
AS. Castiglione M. Goldhirsch A. Senn H-J and for the SAKK and IBCSG
(1993) The Perceived Adjustment to Chronic illness Scale (PACIS): a global
indicator ofcoping for operable breast cancer patients in clinical trials.
Supportive Care Cancer 1: 200-2(8
Hurny C. Bernhard J. Coates AS. Castiglione M. Peterson H Gelber RD and forthe
IBCSG (1994) Timing ofbaseline quality oflife assessment in an international
adjuvant breast cancer trial: its effect on patient self-estimation Ann Oncol 5:
65-74
Hurny C. Bernhard J. Coates AS. Castiglione M. Peterson HF. Gelber RD. Forbes IF.
Rudenstam C-M. Simoncini E. Crivellari D. Goldhirsch A and Senn H-J
(1996a) Impact ofadjuvant therapy on quality oflife in women with node-
positive operable breast cancer. Lancet347: 1279-1284
Hurny C. Bernhard J. Coates AS. Peterson HF. Castiglione-Gertsch M. Gelber RD.
Rudenstam C-M. Collins J. LindtnerJ. Goldhirsch A and Senn H-J (1996b)
Responsiveness of a single-item indicator versus a multi-item scale: assessment
ofemotional wellbeing in an international breast cancer trial. Med Care 34:
234-248
Hurny C. Bernhard J. Gelber RD. Coates AS. Castiglione M. Isley M. Dreher D.
Peterson H. Goldhirsch A and Senn H-J (1992) Quality oflife measures for
patients receiving adjuvant therapy for breast cancer- an international trial.
International Breast Cancer Study Group. LiarJ Cancer 28:118-124
International Breast Csancer Study Group (19%)1 Duration and reintrdion of
adjuvant cheohrapy for node-positive preenopua breast cancer patients.
1Cli Oncol 14:1885-1893
British Journal ofCancer (1998) 78(5), 686-93
International Breast Cancer Study Group (1997) Effectiveness ofadjuvant
chemotherapy in combination with tarnoxifen for node-positive post-
menopausal breast cancer patients- J Clin Oncol 15: 1385-1394
Irvine D. Brown B. Crooks D. RobertsJ and Browne G (1991) Psychosocial
adjustment in women with breast cancer. Cancer 67: 1097-1117
Karjalainen S and Pukkala E (1990) Social class as a prognostic factor in breast
cancer survival. Cancer66: 819-826
Kiebert GM. de Haes JC and van de Vekle CJ (1991 ) The impact ofbreast-
conserving treatment and mastectomy on the quality oflife ofearly-stage breast
cancer patients: a review. J Clin Oncol 9: 1059-1070
Maraste R. Brandt L Olsson H and Ryde Brandt B (1992) Anxiety and depression in
breast cancer patients at start ofadjuvant radiotherapy. Relations to age and
type of su y. Acta Oncol31: 641-643
Maunsell E and Brisson J (1990) Receptor status and psychological adjustment of
breast cancer patients (letter). Lancet336: 47
Maunsell E. Brisson J and Deschenes L (1992) Psychological distress after initial
treatment ofbreast cancer. Assessment ofpotential risk factors. Cancer70:
120-125
Mor V. Malin M and Allen S (1994) Age differences in the psychosocial problems
encountered by breast cancerpatients. MonogrNati CancerInst 191-197
Pozo C. Carver CS. Noriega V. Harris SD. Robinson DS. Ketcham AS. Legaspi A.
Moffat Jr FL and Clark KC (1992) Effects ofmastectomy versus lumpectomy
on emotional adjustment to breast cancer: a prospective study ofthe first year
postsurgery. J Clin Oncol 10: 1292-1298
Priestman TJ and Baum M (1976) Evaluation ofquality oflife in patients receiving
treatment for advanced breast cancer. Lancet i: 899-901
Razavi D. Farvacques C and Delvaux N (1990) Psychosocial correlates ofoestrogen
and progesterone receptors in breast cancer. Lancet335: 931-933
Roberts CS. Cox CE. Reintgen DS. Baile WF and Gibertini M ( 1994) Influence of
physician communication on newly diagnosed breast patients psychologic
adjustment and decision-making. Cancer74: 336-341
Rosenqvist S. Berglund G. Bolund C. FornanderT. Rutqvist LE. Skoog L and
Wtlking N (1993) Lack ofcorrelation between anxiety parameters and
oestrogen receptor status in early breast cancer. EarJ Cancer 29A: 1325-1326
Schtijvers CT. Mackenbach JP. Lutz JM. Quinn MJ and Coleman MP (1995)
Deprivation and survival from breast cancer. BrJ Cancer 72: 738-743
Tjemsland L Soreide JA and Malt UF (1995) Psychosocial factors in women with
operable breast cancer. An association to estrogen receptor status? JPsychosom
Res 39: 875-881
Vtnokur AD. Threatt BA. Vmokur Kaplan D and Satariano WA (1990) The process
ofrecovery from breast cancer for younger and older patients. Changes during
the first year. Cancer65: 1242-1254
von Zerssen D (1976) Klinische Selbstbeurteilungsskalen (KSb-SJ aus dem
MuenchenerPsvchiatrischen Informationssvstem (PSYCHIS Muenchen). Die
Befindlichkeitsskala-Parallelformen Bf-S undBf-S' Manual. Beltz: Weinheim
von Zerssen D (1986) Clinical self-rating scales (CSRS) ofthe Munich Psychiatric
Information System (PSYCHIS Muenchen). In Assessment ofDepression.
N Sartorius and TA Ban (eds). pp. 270-303. Springer Berlin
APPENDIX
International Breast Cancer Study Group: participants
and authors trials VI, VlI
Coor oiating Center M Casiione, A Goldhirsch
Bern, Switzertand (Studies Coordinators),
K Geiser, A Berlinger, G Egli
(Data-Management)
R Maibach, R Pedowsbd
Statistical Center R Gelber (Group Statistician),
Harvard School of Public Health K Price, H Peterson, M Zelen,
and Dana-Farber Cancer Institute, S Geter, A O'Neil
Boston, MA, USA
Qualty of Life Office J Bernhard, Ch Hurmy, H Gusset
Bem, Switzerand
Pathology Office B Gusterson, R Bettelheim,
Institute of Cancer Research, R Reed
Royal Cancer Hspital, Sutton, UK
Data Management Center M Isley, R Hinkle
Frontier Science and Technology
Research Foundation
Amhrt NY, USA
0 Cancer Research Camnpaign 1998Impact on baseline qualityoflife 693
Auckland Breast Cancer Study
Group,
Auckland, New Zealand
Centro di Rifeimento Oncoogco
Avlano, Italy
Spedali Civi & Fondazione
Beretta, Brescia, Italy
Groote Schuur Hospital, Cape
Town, Rep. of South Africa
West Swedish Breast Cancer
Study Group, G6teborg, Sweden
General Hospa
Gorizia. Italy
Sandton Oncology Center
Johannesburg, South Africa
The institute of Oncology,
Lubjana, Slvenia
Madrid Breast Cancer Group,
Madnd, Spain
Anti-Cancer Council of Victoria,
Melume, Aushalla
Royal Adelaide Hospital,
Adelaide, Australia
SirCharles Gairdner Hospital,
Nedlands, Western Australia
Australian New Zealand Breast
Cancer Trials Group (ANZ BCTG)
Mater Hospital
Waratah, Newcastle, Australia
RG Kay, VJ Harvey,
CS Benain, PThorpson,
A Bierre, M Miller, B Hochstein,
A Lethaby, J Webber
D Crivellri, S Monfardini,
E Galligioni, A Veronesi,
A Buonadonna, S Massarut,
C Rossi, E Candiani, A Carbone,
R Vope, M Roncadin,
M Arcicasa, GF Santini, F Villalta,
F Coran, S Morassut
G Marni, E Sironin, P Marpicati,
A Barni, P Grigolato, L Morassi
DM Dent, A Gudgeon,
E Murray, P Steynor, J Toop
CM Rudenstar, A WaNgren,
S Ottosson-L6n, R Hultborn,
G Coldahl-Jdes m, E Cahfin,
J Mattsson, S Hrntberg,
S Jansson, L Ivarsson, 0 Ruusvik,
LG Niklasson, S Dahlin,
G Karlsson, B Linberg,
A Sundc, S Bergegirdh,
H Salander, C Andersson,
M Heideman, Y Hessnan,
0 Nelzen, G Claes, T Rarnhult,
JH Svensson, P Liedberg
S Foladore, L Foghin, G Parnich,
C Bianchi, B Marino, A Murgia,
V Milan
D Vorobiof, M Chasen,
G Fotheringar, G de Muelenaere,
B Skudowitz, C Mohanred,
A Rosengarten
J Lindrter, D Erzen, E Majidc,
B Stabuc, A Plesnicar,
R Golouh, J Lamovec, J Jancar,
I Vrhoved, M Kranberger
H Cortes-Funes, D Mendbola,
C Gravalos, Colomer, M Mendez,
F Cruz Vigo, P Miranda,
A Sierra, F Martinez-Telo,
A Garzon, S Alonso, A Ferrero,
C Vargas
J Collins, P Gregory, P Kitchen,
S Hart, S Neil, M Henderson,
I Russell, TGale, M Pitcher,
R Snyder, R McLennan,
M Schwarz, I Bums, M Green,
R Basser, R Drurrnond,
A Rodger, G Ricardson,
J McKendrick, M Chiprnan
I Olver, A Robertson, P Gill,
ML Carter, PMaWya,
E Yeoh, G Ward, ASY Leong,
J Lommax-Srith, D Hoosfall,
R D'Angelo
M Byrne, G van Hazel, J Dewar,
M Buck, D Ingram, G Sterret
JF Forbes, J Stewart,
D Jackson, R Gourlay, J Bishop,
C Flower, A Widson, S Cox,
S Ackdand, A Bonaventura,
C Harnton, J Denham, P O'Brien,
M Back, S Brae, A Price,
Muragasu, H Foster, D Clarke,
R Sillar, V Clarke, S Brew
University of Sydney,
Dubbo Base Hospital and
Royal Prince Alfred Hospital,
Sydney, Australa
European Institute of Oncology,
Milan, Italy
Ospedale Infermi,
Rimini
Ospedale S Eugenio,
Rome, Italy
Ospedale S Bortolo,
Vicenza, Italy
Toronto Sunnybrook Regional
Cancer Centre
Toronto, Canada
SAKK (Swiss Group for Clinical
Cancer Research):
Inseispa, Bern
Kantonsspital, St Gallen
Ospedale San Giovanni,
Bellinzona
Kantonsspital, Basel
H6pital des Cadolles, NeuhAtel
Kantonsspital, Luzern
Kantonsspital, Zrich
Centre H6pitalier Universitaire,
Lausanne
H6pital Cantonal, Geneva
Kantonsspital GraubOnden, Chur
Swiss Cancer League,
Bern, Switzerland
MHN Tattersall, A Coates,
F Niesche, R West, S Renwidck
J Donovan, P Duval, R J Sirnes,
A Ng, D Glenn, RA North,
J Beith, RG O'Connor, M Rice,
G Stevens, J Grassby,
S Pendlebury, C Mcleod, M Boyer,
A Sulhvan, J Hobbs
A Gddhirsch, G Martinelli,
U Veronesi, A Luini, R Orecchia,
G Vale, M Colleoni, F Nod,
F Peccatori, A Costa, S Zurrida,
P Veronesi, V Sacchini, V Gallirrberti
A Ravaioli, D Tassinari,
G Oliverio, F Barbanbi, P Rinaldi,
E Pini, G Drudi
M Antimi, M Minelli, V Bellini,
R Porzio, E Pernazza,
G Santeusanio, LG Spagnoli
M Magazu, V Fosser,
P Morand, G Scalco, M Balli,
M Gion, S Meli, G Torsello
K Pritchard, D Sutherland,
C Sawka, G Taylor, R Choo,
C Catzavelos, K Roche
MF Fey, E Dreher, H Schneider,
S Aebi, K Buser, J Ludin, G Beck,
H Burgi, A Haenel, JM Luthi,
R Markwaler, F- Altermatt,
M Nandedckar
HU Senn, B ThOrlirnann,
Ch Oehschegei, G Ries, M T6pfer,
U Lorenz, 0 Schditncht, B Spati
F Cavalli, 0 Pagani,
H Neuenschwander, W MOuer,
L Bronz, C Sessa, G Martinelli,
M Ghielrnini, P Lusceb,
E Passega, T Rusca, P Rey,
J Bernier, S Martnoli, E Pedrinis,
G Losa, T Gyr, L Leidi,
G Pastorelli, A Goldhirsch
R Herrnann, JF Harder, 0 K6chIi,
U Epperberger, J Torhorst
D Piguet, P Siegenthaler,
V Barrelet RP Baurarnn
R Joss
B Pestalozzi, C Sauter, V Engeler,
U Hailer, U Metzger, P Huguenin,
R Caduff
L Perey, S Leyvraz, P Anani,
F Gomez, D Welrnan, G Chapuis,
P De Grandi, P Reymond,
M Gillet, JF Delaloye
P Alberto, H Bonnefol, P Schafer,
F Krauer, M Forni, M Aapro, R Egeli,
R Megevand, E Jacot-des-Combes,
A Schindler, B Borisch, S Diebold
F Egli, P Forrer, A Willi, R Steiner,
J Allemann, T ROedi, A Leutenegger,
U Dalla Torre
U Metzger, W Weber,
G Noseda
Britsh Journal ofCancer(1998) 78(5), 686-693 0CancerResearchCampaign 1998